Agnieszka Janeczek

RENOVITE® provides unprecedented retention of therapeutics within the target site, allowing significant dose reduction, lower COGS and improved safety, extending their use case and markets in an injectable, minimally-invasive formulation. First products address a $5.7bn orthobiologics market. Renovos has granted patents, clinical-grade manufacture and a strong scientific and commercial team.